Target RWE at AASLD's The Liver Meeting 2025
Partner with Target RWE to power today’s breakthroughs in hepatology
Unmatched Research in Hepatology
Target RWE is proud to join AASLD’s The Liver Meeting 2025, bringing new real-world insights from our hepatology research network. This year’s presentations highlight emerging evidence in metabolic liver disease, including analyses from the our MASLD cohort that inform how clinicians and researchers track disease progression and cardiovascular risk.
Visit Booth #742 to connect with our team and explore how Target RWE’s evidence platform is advancing hepatology research and development.
Event Details & Target RWE Booth Location
Location: Walter E. Washington Convention Center
Address: 801 Allen Y. Lew Place NW, Washington, DC 20001
Dates: November 7-11, 2025
Booth Location: Target RWE booth #742
Exhibit Hall Hours: Sunday, November 9 & Monday, November 10: 9:30 AM to 5:00 PM
Research Activity at The Liver Meeting
FIB-4 change and MASLD trajectory
Changes in the fibrosis-4 (FIB-4) score accurately reflect the disease trajectory of metabolic dysfunction-associated steatotic liver disease.
As non-invasive tests take center stage in the management of metabolic dysfunction-associated steatotic liver disease (MASLD), questions remain about how best to track disease trajectory. This analysis from the Target RWE’s MASLD cohort explores whether changes in the widely available FIB-4 score can mirror shifts in disease risk—offering a practical alternative when advanced tools like VCTE aren’t available.
Target RWE’s MetALD analysis
Clinical characteristics and outcomes of patients with presumed MASLD who meet MetALD criteria in the TARGET-NASH cohort.
As the conversation around metabolic dysfunction-associated steatotic liver disease (MASLD) evolves, the role of alcohol use is gaining renewed attention. In this TARGET-NASH analysis, researchers examined patients with presumed MASLD who met criteria for metabolic-associated alcohol-related liver disease (MetALD). Despite fewer metabolic risk factors, these individuals experienced cardiovascular events as often—and sooner—than their MASLD counterparts.
Proven Leadership in Hepatology Research
Rooted in decades of leadership within the hepatology community, Target RWE brings together clinical insight and real-world innovation to advance the understanding of liver disease. From pioneering large-scale collaborations like HCV-TARGET to driving regulatory and NIH-backed research, our team has helped set the standard for evidence generation in hepatology.
Today, we apply that same rigor across MASLD/MASH, PBC, HCC, and beyond—leveraging deep longitudinal data, bias-aware analytics, and pragmatic design to deliver evidence that informs care and accelerates development.
At The Liver Meeting 2025, we’re showcasing how Target RWE is transforming real-world data into real clinical impact.
Interested in Target RWE's capabilities?
For detailed information on our solutions, please contact our team.